Prostate Cancer - Pipeline Review, H1 2014

Prostate Cancer - Pipeline Review, H1 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Prostate Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Prostate Cancer

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Prostate Cancer and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Prostate Cancer

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Baxter International Inc. Johnson & Johnson F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Sanofi AstraZeneca PLC Viralytics Ltd. GlaxoSmithKline plc Bioniche Life Sciences, Inc. Genentech, Inc. Daiichi Sankyo Company, Limited Merck & Co., Inc. Takeda Pharmaceutical Company Limited Amorfix Life Sciences Ltd. Ipsen S.A. MediGene AG Bio-Path Holdings, Inc. Jubilant Life Sciences Limited ZIOPHARM Oncology, Inc. Novartis AG Samyang Holdings Corporation Astellas Pharma Inc. GTx, Inc. Pfizer Inc. Teva Pharmaceutical Industries Limited Genmab A/S Aduro BioTech, Inc. Ferring International Center S.A. Celgene Corporation Bayer AG AntiCancer, Inc. Merck KGaA Advaxis, Inc. 4SC AG Anavex Life Sciences Corp. ValiRx Plc AEterna Zentaris Inc. Immunomedics, Inc. Antisense Therapeutics Limited Lorus Therapeutics Inc. Bionomics Limited Nymox Pharmaceutical Corporation Oncothyreon Inc. Compugen Ltd. Patrys Limited ArQule, Inc. Regeneron Pharmaceuticals, Inc. ProMetic Life Sciences Inc. Galectin Therapeutics, Inc. Quest PharmaTech Inc. Synta Pharmaceuticals Corp. Natco Pharma Limited Sareum Holdings plc Oasmia Pharmaceutical AB DiaMedica Inc. Dongkook Pharmaceutical Co., Ltd. Galena Biopharma, Inc. Rexahn Pharmaceuticals, Inc. Merrion Pharmaceuticals Plc Nanobiotix Antigen Express, Inc. Oryzon Genomics S.A. Affitech A/S Isarna Therapeutics GmbH Colby Pharmaceutical Company Mayne Pharma Group Limited Chipscreen Biosciences Ltd CIMAB S.A. Fusion Antibodies Ltd Med Discovery SA Pro-Cure Therapeutics Limited immatics biotechnologies GmbH LIDDS AB Vaxon Biotech Advantagene, Inc. Medeia Therapeutics Ltd. Aileron Therapeutics, Inc. Alethia Biotherapeutics Inc. GenSpera, Inc. Ascenta Therapeutics, Inc. Coronado Biosciences, Inc. MacroGenics, Inc. Provenance Biopharmaceuticals Corp. Antyra, Inc. Ambrx, Inc. Pantarhei Bioscience BV Azaya Therapeutics Incorporated GP Pharm, S.A. IC-MedTech, Inc. Innate Therapeutics Limited Iconic Therapeutics, Inc. ProNAi Therapeutics, Inc. Angion Biomedica Corp. Axelar AB Endocyte, Inc. Omnitura Therapeutics Inc. AndroScience Corporation Pharminox Limited Immutep S.A. NovaLead Pharma Pvt. Ltd. Esperance Pharmaceuticals, Inc. Mirna Therapeutics, Inc. Omeros Corporation TransTech Pharma, Inc. Immunovaccine, Inc. Peptron, Inc. Seek Cellceutix Corporation IGF Oncology, LLC. TVAX Biomedical, Inc. Quintessence Biosciences, Inc. Aprea AB Biokine Therapeutics Ltd. Cylene Pharmaceuticals, Inc. Genelux Corporation WntResearch AB Viventia Biotechnologies Inc. IRX Therapeutics, Inc. Vicus Therapeutics, LLC Oncovir, Inc. Advanced Cancer Therapeutics 3-V Biosciences, Inc. Soricimed Biopharma Inc. Almac Discovery Ltd. VaxOnco Inc BHR Pharma, LLC KAEL-GemVax Co., Ltd. iCeutica, Inc. Incuron, LLC Mebiopharm Co., Ltd. Polaris Group Vaccibody AS DEKK-TEC, Inc. Serometrix, LLC CytoVac A/S Acino Pharma AG Sialix, Inc. Bio-Cancer Treatment International Limited APIM Therapeutics AS EntreChem, S.L. Cold Genesys, Inc. Zensun (Shanghai) Sci & Tech Co., Ltd. Polyplus-transfection SA Kancera AB Vaxeal Holding SA Arrien Pharmaceuticals, LLC Qu Biologics Inc. CZ BioMed Corp Evgen Limited Activartis Biotech GmbH Panacela Labs, Inc. Avipep Pty Ltd ATLAB Pharma SAS Tactic Pharma, LLC Kadmon Corporation, LLC RAPID Pharmaceuticals AG Akshaya Bio Inc. ADC Therapeutics Sarl Foresee Pharmaceuticals, LLC Tolero Pharmaceuticals, Inc. DexTech Medical AB OncoNOx ApS Curadis GmbH PSites Pharma GmbH Pharmedartis GmbH DormaTarg, Inc. Oncology Research International Limited Galileo Research s.r.l. Vasgen Limited Balonco GMBH SillaJen Co. Ltd. Bionature E.A. Ltd. TREAT U, S.A.

To view the table of contents and know more details please visit Prostate Cancer - Pipeline Review, H1 2014